Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00883688
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Concentration and Activity of Lapatinib in Vestibular Schwannomas
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2021-01-12
- Target Recruit Count
- 26
- Registration Number
- NCT00863122
- Locations
- 🇺🇸
House Reserach Institute, Los Angeles, California, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
- Conditions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 1
- Registration Number
- NCT00857714
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00849329
- Locations
- 🇪🇸
GSK Investigational Site, Hospitalet de Llobregat (Barcelona), Spain
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 102
- Registration Number
- NCT00841828
- Locations
- 🇪🇸
Hospital General de Granollers, Granollers, Barcelona, Spain
🇪🇸Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 991
- Registration Number
- NCT00829166
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2019-03-22
- Target Recruit Count
- 58
- Registration Number
- NCT00826241
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT00826267
- Locations
- 🇺🇸
1200.44.01001 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇧🇷1200.44.12005 Boehringer Ingelheim Investigational Site, Ijui, Brazil
🇧🇷1200.44.12007 Boehringer Ingelheim Investigational Site, Natal, Brazil
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00821054
- Locations
- 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00820924
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.